Skip to content
10-K

Annual Report

Polaryx Therapeutics, Inc. PLYX

0001213900-26-033064

← back to feed
Filed
Mar 24, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 1, 2026 47.34M sh
Shares Diluted FY 2025 · Dec 31, 2025 45.42M sh
Shares Diluted FY 2025 · Dec 31, 2024 34.2M sh
Operating Cash Flow FY 2025 · Dec 31, 2025 −$3.94M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$2.57M
Cash And Equivalents FY 2025 · Dec 31, 2025 $5.14M
Cash And Equivalents FY 2025 · Dec 31, 2024 $4.62M
Stockholders Equity FY 2025 · Dec 31, 2025 $4.57M
Stockholders Equity FY 2025 · Dec 31, 2024 $4.71M
Stockholders Equity FY 2025 · Dec 31, 2023 $1.28M
Current Liabilities FY 2025 · Dec 31, 2025 $605K
Current Liabilities FY 2025 · Dec 31, 2024 $289K
Total Liabilities FY 2025 · Dec 31, 2025 $605K
Total Liabilities FY 2025 · Dec 31, 2024 $289K
Current Assets FY 2025 · Dec 31, 2025 $5.17M
Current Assets FY 2025 · Dec 31, 2024 $5M
Total Assets FY 2025 · Dec 31, 2025 $5.17M
Total Assets FY 2025 · Dec 31, 2024 $5M
Eps Diluted FY 2025 · Dec 31, 2025 −$0.20
Eps Diluted FY 2025 · Dec 31, 2024 −$0.89
Eps Basic FY 2025 · Dec 31, 2025 −$0.20
Eps Basic FY 2025 · Dec 31, 2024 −$0.89
Sga Expense FY 2025 · Dec 31, 2025 $1.56M
Sga Expense FY 2025 · Dec 31, 2024 $1.54M
Rd Expense FY 2025 · Dec 31, 2025 $6.27M
Rd Expense FY 2025 · Dec 31, 2024 $2.81M
Net Income FY 2025 · Dec 31, 2025 −$8.99M
Net Income FY 2025 · Dec 31, 2024 −$30.36M
Operating Income FY 2025 · Dec 31, 2025 −$7.82M
Operating Income FY 2025 · Dec 31, 2024 −$4.35M